Ventana Inks Master CDx Deal with Astellas Focusing Initially on FGFR Inhibitor | GenomeWeb

NEW YORK (GenomeWeb) – Roche subsidiary Ventana Medical Systems announced that it will develop tissue-based diagnostics to support drug development programs at Japanese drug firm Astellas Pharma as part of a master collaboration agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.